United Therapeutics Corporation (UTHR) : United Therapeutics Corporation (UTHR) had a healthy money flow of $1.32 million into the stock during the Fridays trading session. The value of bullish trades on upticks was $8.94 million, whereas, investors only sold shares worth $7.62 million on downticks. The stock closed the day with an up-down ratio of 1.17.The money flow in the block trades to the tune of $1.12 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $1.12 million worth of transactions were on upticks. United Therapeutics Corporation (UTHR) stock slid $0.53 intraday and traded at 111.9, a change of -0.47% over previous days close. However, for the week, the company shares are 1.04% compared to previous weeks close.
United Therapeutics Corporation (UTHR) : The highest level United Therapeutics Corporation (UTHR) is projected to reach is $229 for the short term and the lowest estimate is at $95. The consolidated price target from 8 rating analysts who initiate coverage on the stock is $137.88 and the possibility the share price can swing is $41.41.
United Therapeutics Corporation (NASDAQ:UTHR): On Fridays trading session , Opening price of the stock was $113 with an intraday high of $113.43. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $111.29. However, the stock managed to close at $111.41, a loss of 0.91% for the day. On the previous day, the stock had closed at $112.43. The total traded volume of the day was 412,923 shares.
In a related news, The Securities and Exchange Commission has divulged that Rothblatt Martine A, director officer (Chairman & CEO) of United Therapeutics Corp, had unloaded 1,284 shares at an average price of $113.46 in a transaction dated on July 21, 2016. The total value of the transaction was worth $145,683.
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin, Tyvaso (treprostinil), Adcirca (tadalafil), Remodulin Implantable System, Orenitram Combination Therapy, Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb, for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation, for the treatment of End-stage lung disease; UV-4B, for the treatment of Dengue and influenza, and Glycobiology Antiviral Agents, for the treatment of a spectrum of agents against viral infectious diseases, among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.